Bioxyne Secures First Orders for GMP Psilocybin Capsules in Emerging Psychedelic Therapy Market

An update from Bioxyne Limited ( (AU:BXN) ) is now available.

Bioxyne Limited, through subsidiary Breathe Life Sciences, has begun commercial supply of GMP-manufactured psilocybin capsules to authorised prescribers in Queensland and Western Australia for use in treatment-resistant depression and other mental health research. The company’s BLSPSIL25 capsules meet Australian and international pharmaceutical standards, positioning Bioxyne as an early mover in Australia’s tightly regulated psychedelic-assisted therapy market.

Initial orders cover 250 doses to treat around 60 patients over the next year, a small slice of an estimated 300,000 Australians living with treatment-resistant depression, but management says manufacturing can scale significantly to meet growing demand. With mental illness affecting a large portion of the population and global psychedelic drug markets forecast to expand rapidly, the move validates Bioxyne’s strategic investment in psychedelic therapeutics and could open a pathway to larger commercial opportunities if clinical and regulatory momentum continues.

The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.04 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.

More about Bioxyne Limited

Bioxyne Limited is an Australian pharmaceutical company listed on the ASX that focuses on developing and commercialising innovative medicines and active pharmaceutical ingredients. Through its wholly owned subsidiary Breathe Life Sciences, the company operates as a TGA GMP-licensed manufacturer, supplying pharmaceutical-grade psychedelic products for regulated therapeutic use in Australia and potentially international markets.

Average Trading Volume: 1,744,521

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$89.6M

Learn more about BXN stock on TipRanks’ Stock Analysis page.